CHMP positive for Finlee + trametinib for the treatment of low and high grade glioma – Novartis
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.